7d
Zacks Investment Research on MSNNevro (NVRO) Reports Q4 Loss, Tops Revenue EstimatesNevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are adjusted ...
Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...
Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...
Nevro Corp (NYSE:NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is ...
As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alpha Teknova (TKNO – Research Report), Wave Life Sciences ...
NEVRO ($NVRO) posted quarterly earnings results on Tuesday, March 4th. The company reported earnings of -$0.64 per share, beating estimates of -$0.79 by $0.15. The ...
On a per-share basis, the Redwood City, California-based company said it had a loss of $1.41. Losses, adjusted for one-time gains and costs, were 64 cents per share. The results surpassed Wall Street ...
What Are the BATMMAAN Stocks? If you're ready to move beyond Magnificent Seven stocks, there's a new acronym on Wall Street with one key addition.
Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results